Meda has signed an exclusive licensing agreement with Medivir for Xerese. Xerese is used for topical treatment of cold sores. Meda’s exclusive rights cover the US, Canada and Mexico. Meda will pay Medivir a total of $5 million in up-front and pre-launch milestones. Meda will also pay Medivir double-digit royalties on sales.